Albany Molecular Research Inc. ("Albany" or the Company) is a contract research and manufacturing organization that provides drug discovery, development, and manufacturing to the pharmaceutical and biotechnology industries.

According to the Complaint, on June 5, 2017, the Board caused the Company to enter into an agreement and plan of merger, pursuant to which each share of common stock of Albany will be converted into the right to receive $21.75 in cash.

The Complaint alleges that on July 3, 2017, in order to convince Albany stockholders to vote in favor of the Proposed Merger, the Board authorized the filing of a materially incomplete and misleading Preliminary Proxy Statement with the Securities and Exchange Commission, in violation of Sections 14(a) and 20(a) of the Exchange Act.

The first identified case was voluntarily dismissed on October 25, 2017.

A related action was filed in the Northern District of New York and docketed under 17-CV-01179.

On December 29, 2017, Plaintiff filed a Notice of Voluntary Dismissal.